SecBot SecBot
PRESS-RELEASE ·Filed Aug 13, 2026

CABA

Cabaletta Bio
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor for updates on the registrational myositis trial data in mid-2027 and initiation of the SSc-ILD cohort in 4Q26. The cash runway into mid-2027 provides a buffer, but with no near-term catalysts, the stock is likely to trade on pipeline sentiment and broader biotech sector trends.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.71
T+0 close · Aug 13, 2026 · via day close
Latest settled
−52.03%
T+60 · $1.30
Vs SPY
−46.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $2.71entry
  2. T+1 · 3mo ago +1.48%α +1.67% · $2.75
  3. T+5 · 3mo ago +17.71%α +19.68% · $3.19
  4. T+20 · 2mo ago +0.74%α +2.49% · $2.73
  5. T+60 · 11d ago −52.03%α −46.55% · $1.30
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue. The company highlighted progress in its registrational myositis trial (data mid-2027, BLA 2H27) and plans to initiate a second registrational cohort in SSc-ILD in 4Q26. Cash position strengthened to $225.1M post a $150M May offering, extending runway into mid-2027, but the EPS beat is modest and pipeline milestones remain distant, making this a neutral event.

Key Financial Metrics

EPS
−$0.34
est −$0.37 · +8.1%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Q2 2026 EPS of -$0.34 beat consensus of -$0.37 by 8.1%
  • Cash, cash equivalents, and short-term investments were $225.1M as of June 30, 2026, up from $133.6M at year-end 2025
  • Registrational RESET-Myositis data expected mid-2027 with BLA submission in 2H27
  • SSc-associated ILD registrational cohort of ~25 patients expected to initiate in 4Q26
  • PC-free approach being incorporated into RESET-MG trial
  • ElevateBio selected as second CDMO for clinical and commercial manufacturing

Financial Impact

EPS beat of $0.03 (8.1%) vs consensus; cash position increased by $91.5M from year-end 2025 to $225.1M

epscash

Risk Factors

  • Clinical trial failure or delay in myositis or SSc-ILD programs
  • Cash burn rate may require additional financing before mid-2027 if milestones slip
  • Competition from other CAR-T therapies in autoimmune diseases

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3344398

Track record

29 reports on CABA

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026